| Prenosis Sepsis ImmunoScore |
Hospitals evaluating transparent sepsis risk stratification that combines clinical data and biomarkers with EMR-integrated review for suspected sepsis workflows. |
FDA De Novo DEN230036 intended use, patient eligibility, blood-culture-order requirement, 24-hour risk window, and prescription-use limits. |
4 official sources |
| Anumana ECG-AI |
Health systems evaluating FDA-cleared cardiac detection support that can fit existing ECG, EHR, and cardiology referral workflows. |
Which ECG-AI algorithm is in scope: low ejection fraction, pulmonary hypertension, cardiac amyloidosis, or another pipeline module. |
6 official sources |
| Eko Health SENSORA |
Health systems and clinics that want to add clinician-reviewed cardiac disease detection signals to routine intake, primary care, or outpatient cardiovascular screening workflows. |
Which SENSORA algorithm, device, software version, compatible stethoscope, patient population, geography, and FDA-cleared indication are in scope. |
6 official sources |
| AliveCor Kardia 12L |
Clinical teams that need portable 12-lead ECG acquisition with AI-supported cardiac findings in supervised, trained-user workflows. |
Which Kardia 12L device, KAI 12L algorithm version, cardiac determinations, geography, and labeling are in scope for the deployment. |
6 official sources |
| Philips Cardiologs Holter |
Cardiology and ambulatory monitoring teams that need AI-supported ECG review while preserving clinician overread, annotation, reporting, and escalation workflows. |
Which product is in scope: Cardiologs Holter Platform, Philips Holter Analysis System, API integration, supported ECG source, algorithm version, and geography. |
6 official sources |
| Tempus |
Oncology and life-sciences teams evaluating AI-enabled precision medicine workflows that combine molecular, clinical, imaging, and real-world data. |
Which Tempus product is in scope: One, Hub, Now, Lens, Pixel, Next Pathways, Next Trials, assays, or algos. |
5 official sources |
| Tempus One |
Oncology and precision-medicine teams that need governed access to Tempus patient insights, test status, guideline context, trial matching, and multimodal data summaries. |
Whether Tempus One is being used in Hub, an EHR integration, Lens, a provider workflow, or a life-sciences research workflow. |
6 official sources |
| SOPHiA GENETICS |
Labs and health systems that need standardized analytics for precision oncology, rare disease, and multimodal data workflows. |
Whether the selected module is diagnostic, research, or local-validation use. |
3 official sources |
| Guardant InfinityAI |
Organizations exploring clinical-genomic oncology cohorts, biomarker hypotheses, testing value, and longitudinal cancer data strategy. |
Which InfinityAI module, data library, or Guardant product feature is being evaluated. |
3 official sources |
| ArteraAI Prostate |
Prostate cancer programs that need an FDA-authorized, clinician-ordered AI risk-stratification input tied to pathology images, clinical data, and guideline-aware decision workflows. |
Whether the patient population matches the localized, non-metastatic, post-radical-prostatectomy, or metastatic hormone-sensitive prostate workflow being considered. |
5 official sources |
| Avenda Unfold AI |
Prostate cancer teams evaluating a regulated, physician-reviewed mapping input for focal therapy suitability, biopsy planning, ablation planning, or shared treatment decisions. |
FDA 510(k) K221624, current labeling, indications for use, trained-user requirements, and whether the evaluated product version is Unfold AI or an older iQuest-branded release. |
6 official sources |
| Unlearn |
Sponsors exploring smaller or more informative control arms, single-arm study context, interim looks, or trial power improvements with statistical review. |
Which disease-specific Digital Twin Generator and study design are in scope. |
4 official sources |
| Owkin K Pro |
Research teams that need governed analysis across genomic, transcriptomic, spatial, clinical, and literature data for discovery or biomarker work. |
Which datasets, AI skills, and biomedical tasks are available for the research question. |
3 official sources |
| Caris Life Sciences |
Oncology teams evaluating molecular profiling and AI-assisted insight workflows for cancer care and research. |
Which test, report, or AI insight is being used and its exact clinical role. |
3 official sources |
| Flatiron Assist |
Oncology teams that need EHR-embedded pathway support tied to NCCN content, local preferences, biomarker context, and operational reporting. |
Which cancers, regimens, biomarkers, pathways, and clinical-trial workflows are supported. |
2 official sources |
| Truveta |
Research and evidence teams that need daily updated EHR, claims, mortality, imaging, multiomics, and other linked data with reproducibility controls. |
Which Truveta product is in scope: Data, Studio, Intelligence, Evidence, Tru, or Truveta Language Model-supported workflows. |
6 official sources |
| Deep 6 AI |
Research organizations that need faster protocol feasibility and patient identification while maintaining investigator, IRB, privacy, and site-review controls. |
Which workflow is in scope: cohort discovery, site feasibility, patient matching, chart abstraction, sponsor search, or network analytics. |
4 official sources |
| Dyania Health Synapsis |
Research organizations that need faster chart review and eligibility screening while preserving study-team, clinician, IRB, and privacy controls. |
Which Synapsis workflow is in scope: trial screening, protocol feasibility, registry abstraction, chart review, or real-world evidence extraction. |
4 official sources |
| TriNetX |
Research organizations that need cohort feasibility, site intelligence, and real-world data analytics before launching or adapting clinical trials. |
Which TriNetX module, dataset, geography, and trial workflow are in scope: feasibility, protocol design, site identification, recruitment planning, or RWE. |
4 official sources |
| Medidata AI |
Sponsors and CROs that already manage regulated trial operations and need auditable AI support across study design, execution, data oversight, and evidence planning. |
Which Medidata AI capability is in scope: Dot, protocol optimization, study feasibility, integrated evidence, synthetic control arm, data management, or operational monitoring. |
4 official sources |
| ConcertAI |
Oncology sponsors, CROs, research networks, and cancer programs that need governed real-world evidence or trial intelligence built around oncology data. |
Which ConcertAI product is in scope: PrecisionExplorer, PrecisionTRIALS, PrecisionGTM, Precision360, CancerLinQ, or a trial operations workflow. |
3 official sources |
| Aetion Evidence Platform |
Evidence teams that need guardrailed, auditable RWE workflows across claims, EHR, registry, or other longitudinal datasets. |
Which Aetion product is being used: Evidence Platform, Discover, Activate, Substantiate, Generate, Science and Research services, or AetionAI-supported workflows. |
4 official sources |
| nference nSights |
Research teams exploring patient cohorts, multimodal data signals, drug or diagnostic development questions, and code-free RWE workflows. |
Which nSights application, dataset, modality, institution source, or analytics tier is available for the research question. |
4 official sources |
| KidneyIntelX.dkd |
Care teams that need a regulated kidney-risk stratification workflow with lab operations, clinician review, and treatment-planning follow-through. |
Whether the patient population matches the FDA-authorized intended use for adults with type 2 diabetes and early-stage chronic kidney disease. |
5 official sources |
